Volume 20 Issue 8
Aug.  2022
Turn off MathJax
Article Contents
Article Navigation >  Chinese Journal of General Practice  > 2022  >  20(8): 1392-1395
LI Lun-shen, WU Lian-guo, LIANG Bo-cheng, XU Chao, SHI Xiao-lin, WEI Bing, LI Yan-hua, LI Min. Evaluation of the preventive and curative effects of Liuwei Dihuang Pills on the postmenopausal osteoporosis with the type of kidney-yin deficiency[J]. Chinese Journal of General Practice, 2022, 20(8): 1392-1395. doi: 10.16766/j.cnki.issn.1674-4152.002605
Citation: LI Lun-shen, WU Lian-guo, LIANG Bo-cheng, XU Chao, SHI Xiao-lin, WEI Bing, LI Yan-hua, LI Min. Evaluation of the preventive and curative effects of Liuwei Dihuang Pills on the postmenopausal osteoporosis with the type of kidney-yin deficiency[J]. Chinese Journal of General Practice, 2022, 20(8): 1392-1395. doi: 10.16766/j.cnki.issn.1674-4152.002605
shu

Evaluation of the preventive and curative effects of Liuwei Dihuang Pills on the postmenopausal osteoporosis with the type of kidney-yin deficiency

doi: 10.16766/j.cnki.issn.1674-4152.002605
  • 1.

    The Second Clinical Medical College of Zhejiang Chinese Medical University, Hangzhou, Zhejiang 310053, China

Funds:

 2019ZQ026

 2021ZB144

  • Received Date: 2021-06-07
    Available Online: 2022-09-26
    Abstract
  •   Objective  To evaluate the effects of Liuwei Dihuang Pills on the bone density, bone turnover markers and quality of life in the postmenopausal osteoporosis patients with the type of kidney yin deficiency.  Methods  One hundred and twenty patients with postmenopausal osteoporosis characterized by kidney yin deficiency were involved in the present study, which were collected from January 2019 to June 2019 in the Second Clinical Medical College of Zhejiang Chinese Medical University. The 120 cases of patients were randomly divided into Liuwei Dihuang Pills group and the control one, with 60 cases in each group. The patients in every group were treated for 1 year, followed by the examination of serum N-terminal propeptide of type Ⅰ collagen(P1NP), β crosslinked C-telopeptide of type Ⅰ collagen(β-CTX), and bone mineral density of lumbar and hip before and after treatment. Meantime, SF-36 scale was used to evaluate the effects of treatment on the quality of life of patients in each group.  Results  Remarkable change was observed in the serum P1NP, β-CTX and the bone mineral density of the lumbar spine and hip of the patients in both groups after treatment, and there were significantly statistical differences in the average percentage changes in serum P1NP, β-CTX, and bone mineral density of the lumbar spine and hip between the two groups (P1NP: t=-12.902, P < 0.001; β-CTX: t=-3.646, P < 0.001; lumbar spine: t=13.814, P < 0.001; hip: t=21.606, P < 0.001). There was no significant difference on the basic SF-36 scores between the two groups (P>0.05). Interestingly, it was observed that the SF-36 scale score in the Liuwei Dihuang Pills group was higher than that in the control group [(122.60±3.25) points vs. (115.62±2.96) points, t=11.743, P < 0.001)].  Conclusion  The treatment with Liuwei Dihuang Pills can result in the significant decrease in the serum levels of bone turnover markers, increase in the bone mineral density of the waist and hip, and improvement of quality of life in the postmenopausal osteoporosis patients characterized by the type of kidney yin deficiency.

     

    • FullText(HTML)
  • loading
    • References(21)
  • [1]
    陈琳洁, 李志军. 原发性骨质疏松症诊断与治疗[J]. 中华全科医学, 2020, 18(10): 1619-1620. http://www.zhqkyx.net/article/id/5c756c38-3de0-43c5-af82-69be383bf5b2

    CHEN L J, LI Z J. Diagnosis and treatment of primary osteoporosis[J]. Chinese Journal of General Practice, 2020, 18(10): 1619-1620. http://www.zhqkyx.net/article/id/5c756c38-3de0-43c5-af82-69be383bf5b2
    [2]
    何跃辉, 陈狄, 高谦, 等. 围绝经期和绝经后女性骨密度的变化及其相关危险因素分析[J]. 中国骨质疏松杂志, 2019, 25(2): 185-188, 211. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGZS201902010.htm

    HE Y H, CHEN D, GAO Q, et al. Changes in bone mineral density and related risk factors in peri-menopausal and postmenopausal women[J]. Chinese Journal of Osteoporosis, 2019, 25(2): 185-188, 211. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGZS201902010.htm
    [3]
    ENSURD K E, CRANDALL C J. Osteoporosis[J]. Ann Intern Med, 2018, 168(4): 306-307. doi: 10.7326/L17-0586
    [4]
    李建军, 庄学伟, 乔晓鸣. 阿法骨化醇联合钙剂对老年性骨质疏松患者骨钙素、Ⅰ型胶原C端异构肽水平及骨密度的影响[J]. 中国老年学杂志, 2018, 38(23): 5760-5762. https://www.cnki.com.cn/Article/CJFDTOTAL-ZLXZ201823052.htm

    LI J J, ZHUANG X W, QIAO X M. Effects of alfacalcidol combined with calcium on osteocalcin, C-terminal isomertide of type Ⅰ collagen and bone mineral density in senile osteoporosis patients[J]. Chinese Journal of Gerontology, 2018, 38(23): 5760-5762. https://www.cnki.com.cn/Article/CJFDTOTAL-ZLXZ201823052.htm
    [5]
    冯成桢, 李俊伟, 李琰华. 钙剂及维生素D治疗原发性骨质疏松症的有效性与安全性研究进展[J]. 中华全科医学, 2020, 18(4): 642-645. doi: 10.16766/j.cnki.issn.1674-4152.001319

    FENG C Z, LI J W, LI Y H. Progress in the efficacy and safety of calcium and vitamin D in the treatment of primary osteoporosis[J]. Chinese Journal of General Practice, 2020, 18(4): 642-645. doi: 10.16766/j.cnki.issn.1674-4152.001319
    [6]
    姜朝阳, 谢兴文, 徐世红, 等. 六味地黄丸治疗绝经后骨质疏松症的研究进展[J]. 中医正骨, 2020, 32(4): 38-40, 43. https://www.cnki.com.cn/Article/CJFDTOTAL-ZYZG202004008.htm

    JIANG C Y, XIE X W, XU S H, et al. Advancement of research on Liuwei Dihuang Wan for treatment of postmenopausal osteoporosis[J]. The Journal of Traditional Chinese Orthopedics and Traumatology, 2020, 32(4): 38-40, 43. https://www.cnki.com.cn/Article/CJFDTOTAL-ZYZG202004008.htm
    [7]
    中华中医药学会. 绝经后骨质疏松症(骨痿)中医药诊疗指南(2019年版)[J]. 中医正骨, 2020, 32(2): 1-13. https://www.cnki.com.cn/Article/CJFDTOTAL-ZYZG202002001.htm

    China Association of Traditional Chinese Medicine. Guidelines for the Diagnosis and treatment of postmenopausal osteoporosis with traditional Chinese medicine (2019 edition)[J]. The Journal of Traditional Chinese Orthopedics and Traumatology, 2020, 32(2): 1-13. https://www.cnki.com.cn/Article/CJFDTOTAL-ZYZG202002001.htm
    [8]
    邵加龙, 蔡春岳, 杜薛平, 等. 益肾补髓膏联合碳酸钙D3、阿法骨化醇治疗骨质疏松症的临床研究[J]. 现代中西医结合杂志, 2021, 30(4): 427-429, 438. https://www.cnki.com.cn/Article/CJFDTOTAL-XDJH202104020.htm

    SHAO R L, CAI C Y, DU X P, et al. Clinical study of Yishen Bumi ointment combined with calcium carbonate D3 and alfacalcidol in the treatment of osteoporosis[J]. Modern Journal of Integrated Traditional Chinese and Western Medicine, 2021, 30(4): 427-429, 438. https://www.cnki.com.cn/Article/CJFDTOTAL-XDJH202104020.htm
    [9]
    徐玉禄, 王群, 邢亚群, 等. 精骨补骨颗粒治疗绝经后骨质疏松症38例临床观察[J]. 中华全科医学, 2018, 16(7): 1188-1191. doi: 10.16766/j.cnki.issn.1674-4152.000327

    XU Y L, WANG Q, XING Y Q, et al. Clinical observation on 38 cases of postmenopausal osteoporosis treated with Jinggu Bugu granule[J]. Clinical observation on 38 cases of postmenopausal osteoporosis treated with Jinggu Bugu granule, 2018, 16(7): 1188-1191. doi: 10.16766/j.cnki.issn.1674-4152.000327
    [10]
    CAMACHO P M, PETAK S M, BINKLEY N, et al. American association of clinical endocrinologists/American college of endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis-2020 update[J]. Endocr Pract, 2020, 26(Suppl 1): 1-46.
    [11]
    张志宏, 邢娜, 彭东辉, 等. 中药抗骨质疏松作用及机制的研究进展[J]. 中国药房, 2021, 32(3): 374-379. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGYA202103022.htm

    ZHANG Z H, XING N, PENG D H, et al. Research progress on the effect and mechanism of traditional Chinese medicine on osteoporosis[J]. China Pharmacy, 2021, 32(3): 374-379. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGYA202103022.htm
    [12]
    傅繁誉, 黄泽青, 孙继高, 等. 基于网络药理学的济生肾气丸治疗骨质疏松症的分子机制研究[J]. 中国骨质疏松杂志, 2020, 26(10): 1462-1469, 1513. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGZS202010015.htm

    FU F Y, HUANG Z Q, SUN J G, et al. Study on the molecular mechanism of Jisheng Shenqi pill for the treatment of osteoporosis based on network pharmacology[J]. Chinese Journal of Osteoporosis, 2020, 26(10): 1462-1469, 1513. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGZS202010015.htm
    [13]
    华仲森, 陈之青. 绝经后骨质疏松性腰椎骨折患者血清β-CTx、P1NP的水平及意义[J]. 中国老年学杂志, 2018, 38(7): 1642-1643. https://www.cnki.com.cn/Article/CJFDTOTAL-ZLXZ201807049.htm

    HUA Z S, CHEN Z Q. Serum levels of β-CTx and P1NP in postmenopausal patients with osteoporotic lumbar fractures and their significance[J]. Chinese Journal of Gerontology, 2018, 38(7): 1642-1643. https://www.cnki.com.cn/Article/CJFDTOTAL-ZLXZ201807049.htm
    [14]
    YAO P, BENNETT D, MAFHAM M, et al. Vitamin D and calcium for the prevention of fracture: A systematic review and meta-analysis[J]. JAMA Netw Open, 2019, 2(12): e1917789. DOI: 10.1001/jamanetworkopen.2019.17789.
    [15]
    ZHOU J, LIU B, QIN M Z, et al. Fall prevention and anti-osteoporosis in osteopenia patients of 80 years of age and older: A randomized controlled study[J]. Orthop Surg, 2020, 12(3): 890-899.
    [16]
    CHIODINI I, BOLLALND M J. Calcium supplementation in osteoporosis: Useful or harmful?[J]. Eur J Endocrinol, 2018, 178(4): D13-D25.
    [17]
    王伟, 万雷, 柴爽, 等. 骨质疏松症的中医病因病机和分期治疗[J]. 中医正骨, 2018, 30(2): 29-30. https://www.cnki.com.cn/Article/CJFDTOTAL-ZYZG201802007.htm

    WANG W, WAN L, CAI S, et al. TCM etiology, pathogenesis and staging treatment of osteoporosis[J]. The Journal of Traditional Chinese Orthopedics and Traumatology, 2018, 30(2): 29-30. https://www.cnki.com.cn/Article/CJFDTOTAL-ZYZG201802007.htm
    [18]
    肖菲, 高毅, 师伟, 等. 绝经后骨质疏松症中医证型与握力的研究[J]. 中国骨质疏松杂志, 2021, 27(2): 167-171. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGZS202102006.htm

    XIAO F, GAO Y, SHI W, et al. Study on TCM syndromes and grip strength in postmenopausal osteoporosis[J]. Chinese Journal of Osteoporosis, 2021, 27(2): 167-171. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGZS202102006.htm
    [19]
    石敏, 赵继荣, 薛旭, 等. 基于"脾主肉、肾主骨"理论探讨绝经后骨质疏松症的OPG/RANK/RANKL信号调控机制[J]. 中国骨质疏松杂志, 2019, 25(9): 1336-1339, 1356. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGZS201909027.htm

    SHI M, ZHAO J R, XUE X, et al. Study on the mechanism of OPG/RANK/RANKL signal regulation on postmenopausal osteoporosis based on the spleen governing muscle and kidney governing bone theory[J]. Chinese Journal of Osteoporosis, 2019, 25(9): 1336-1339, 1356. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGZS201909027.htm
    [20]
    梁博程, 史晓林, 许超, 等. 基于中药系统药理学方法研究六味地黄丸治疗骨质疏松症的药效成分、作用靶点及作用特点[J]. 中医正骨, 2019, 31(4): 1-7. https://www.cnki.com.cn/Article/CJFDTOTAL-ZYZG201904002.htm

    LIANG B C, SHI X L, XU C, et al. A study of pharmacodynamic components, action targets and characteristics of Liuwei Dihuang Wan in treatment of osteoporosis using traditional chinese medicine systems pharmacology approach[J]. The Journal of Traditional Chinese Orthopedics and Traumatology, 2019, 31(4): 1-7. https://www.cnki.com.cn/Article/CJFDTOTAL-ZYZG201904002.htm
    [21]
    于雪冰, 马建强, 汪栋, 等. 六味地黄丸治疗绝经后骨质疏松症肾阴虚证对骨钙素、骨密度及JAK/STAT信号通路的影响[J]. 中药材, 2020, 43(3): 734-737.

    YU X B, MA J Q, WANG D, et al. Effect of Liuwei Dihuang pill on osteocalcin, bone mineral density and JAK/STAT signaling pathway in the treatment of kidney Yin deficiency syndrome of postmenopausal osteoporosis[J]. Journal of Chinese Medicinal Materials, 2020, 43(3): 734-737.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Tables(4)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (369) PDF downloads(14) Cited by()
    Proportional views
    Related

    Address：No. 287, Changhuai Road, Bengbu, Anhui Province, 233004, P.R.ChinaphoneNo：0552-3066635； 0552-3051890Email：zhqkyx@163.com

    Copyright © Chinese Journal of General Practice皖ICP备2020018345号-2

    Supported by: Beijing Renhe Information Technology Co., Ltd.    

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return